
Keywords: 7â+â3; cytarabine 7 days and daunorubicin (3 days); AE; adverse event; alloHSCT; allogeneic hematopoietic stem cell transplant; AML; acute myeloid leukemia; AML-MRC; AML with myelodysplasia-related changes; AR; allelic ratio; BSC; best supportive care